Scientific publications

Scientific articles authored by Novo Nordisk

The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.

37 results found.
Showing results 1-20
PreviousPrevious 1 2 NextNext
Journal Author Year
Clinical Drug Investigation

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Kupcova V ; Arold G ; Roepstorff C ; Hojbjerre M ; Klim S ; Haahr H 2014
Clinical Pharmacokinetics

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

Kiss I ; Arold G ; Roepstorff C ; Bottcher SG ; Klim S ; Haahr H 2014
Clinical Therapeutics

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Hompesch M ; Morrow L ; Watkins E ; Roepstorff C ; Thomsen HF ; Haahr H 2014
Diabetes Obesity and Metabolism

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

Mathieu C ; Rodbard HW ; Cariou B ; Handelsman Y ; Philis-Tsimikas A ; Francisco AMO ; Rana A ; Zinman B 2014
Diabetes Obesity and Metabolism

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Evans M ; Wolden M ; Gundgaard J ; Chubb B ; Christensen T 2014

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Koehler G ; Heller S ; Korsatko S ; Roepstorff C ; Rasmussen S ; Haahr H ; Pieber TR 2014
Drugs and Aging

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus

Korsatko S ; Deller S ; Mader JK ; Glettler K ; Koehler G ; Treiber G ; Urschitz M ; Wolf M ; Hastrup H ; Sondergaard F ; Haahr H ; Pieber TR 2014
Endocrine Practice


Rodbard HW ; Gough S ; Lane W ; Korsholm L ; Bretler DM ; Handelsman Y 2014
Pediatric Diabetes

Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes

Biester T ; Blaesig S ; Remus K ; Aschemeier B ; Kordonouri O ; Granhall C ; Sondergaard F ; Kristensen NR ; Haahr H ; Danne T 2014
Advances in Therapy

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

Philis-Tsimikas A ; Brod M ; Niemeyer M ; Francisco AMO ; Rothman J 2013

Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec

Steensgaard DB ; Schluckebier G ; Strauss HM ; Norrman M ; Thomsen JK ; Friderichsen AV ; Havelund S ; Jonassen I 2013
Clinical Drug Investigation

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

Korsatko S ; Deller S ; Koehler G ; Mader JK ; Neubauer K ; Adrian CL ; Thomsen H ; Haahr H ; Pieber TR 2013
Diabetes Care

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

Gough SCL ; Bhargava A ; Jain R ; Mersebach H ; Rasmussen S ; Bergenstal RM 2013
Diabetes Care

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

Meneghini L ; Atkin SL ; Gough SCL ; Raz I ; Blonde L ; Shestakova M ; Bain S ; Johansen T ; Begtrup K ; Birkeland KI 2013
Diabetes Obesity and Metabolism

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials

Freemantle N ; Evans M ; Christensen T ; Wolden ML ; Bjorner JB 2013
Diabetes Obesity and Metabolism

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

Ratner RE ; Gough SCL ; Mathieu C ; Del Prato S ; Bode B ; Mersebach H ; Endahl L ; Zinman B 2013
Diabetes Obesity and Metabolism

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

Philis-Tsimikas A ; Del Prato S ; Satman I ; Bhargava A ; Dharmalingam M ; Skjoth TV ; Rasmussen S ; Garber AJ 2013
Diabetes Obesity and Metabolism

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

Onishi Y ; Ono Y ; Rabol R ; Endahl L ; Nakamura S 2013
Diabetic Medicine

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal- bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN (R) Basal-Bolus Type 1): 2-year results of a randomized clinical trial

Bode BW ; Buse JB ; Fisher M ; Garg SK ; Marre M ; Merker L ; Renard E ; Russell-Jones DL ; Hansen CT ; Rana A ; Heller SR 2013
Diabetic Medicine

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

Rodbard HW ; Cariou B ; Zinman B ; Handelsman Y ; Philis-Tsimikas A ; Skjoth TV ; Rana A ; Mathieu C 2013